Abeona Therapeutics (ABEO) vs Emmis Acquisition (EMIS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Emmis Acquisition (EMIS) has outperformed Abeona Therapeutics (ABEO) over the past year, gaining 4.4% versus a loss of 46.0%. Abeona Therapeutics is the larger company by market cap ($165.3 million vs $163.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABEO | EMIS |
|---|---|---|
| Share price | $2.42 | $10.36 |
| Market cap | $165.31M | $163.36M |
| 1-day change | -1.22% | +0.15% |
| YTD return | -54.08% | +4.07% |
| 1-year return | -45.98% | +4.39% |
| 5-year return | -86.74% | — |
| EPS (TTM) | $-1.16 | — |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $5.82M | — |
| Net income (latest FY) | $71.18M | — |
| Gross margin | 73.68% | — |
| Operating margin | -1536.91% | — |
| Net margin | 1223.08% | — |
| 52-week high | $7.65 | $10.38 |
| 52-week low | $2.09 | $9.92 |
| Distance from 52-week high | -68.37% | -0.24% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +542.98% | — |
| Average volume | 1.66M | 16.19K |
| Shares outstanding | 68.31M | 11.94M |
| Employees | 226 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EMIS has outperformed ABEO by 50.4 percentage points over the past year.
About Abeona Therapeutics
ABEO stock →Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa.
Health Care · Biotechnology: Pharmaceutical Preparations · 226 employees
About Emmis Acquisition
EMIS stock →Emmis Acquisition Corp. focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses.
Health Care · Biotechnology: Pharmaceutical Preparations
ABEO vs EMIS FAQ
Which is bigger, Abeona Therapeutics or Emmis Acquisition?
Abeona Therapeutics (ABEO) is larger, with a market capitalization of $165.31M compared with $163.36M for Emmis Acquisition (EMIS).
Which stock has performed better over the past year, ABEO or EMIS?
EMIS returned +4.39% over the past 12 months, compared with -45.98% for ABEO (price return, excluding dividends). Past performance does not predict future results.
Are Abeona Therapeutics and Emmis Acquisition in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.